Our capabilities are wide ranging and include the use of translational technology, such as UV radiation to induce localised inflammation and laser doppler to measure blood flow; plasma/tissue sample collection to establish PK/PD relationships and measure inflammatory biomarkers, and transcriptomic analysis to determine mechanistic aspects of disease progression and predict responders / non-responders to NCE analgesics.
Examples of the models we offer extend to the following:
- CCI (Bennett) model of neuropathic pain
- STZ-induced diabetic neuropathy
- Chemotherapy-induced neuropathy, (Oxaliplatin)
- CFA / carrageenan / capsaicin / formalin inflammatory pain
- MIA / CFA osteoarthritis joint pain
- Acute mechanistic pain models, e.g. NGF
- Ultraviolet light (UV) burn
Examples of end points:
- Weight-bearing (mechanical hypersensitivity)
- Hargeaves (thermal hyperalgesia)
- Von Frey hairs (tactile allodynia)
- Randall Selitto (tactile hyperalgesia)
- Plethysmometer (paw volume)
- Hot/cold plate (allodynia)
- LABORAS automated complex behavioural assessment (e.g. locomotor activity)
- Laser doppler (cutaneous blood flow)
- EEG/sleep
- Inflammatory cytokine analysis (e.g. synovial fluid markers)
- PK and tissue sampling (e.g. spinal cord, DRG’s)
This list is not exhaustive, we are always developing new areas of discovery within our preclinical field of expertise. If there is something particular that is not listed here please do contact us.
